Aura Biosciences, Inc. Exchange Rate Effect on Cash
Aura Biosciences, Inc. (AURA) reported Exchange Rate Effect on Cash of -$200.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-11
- Aura Biosciences, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2026-03-31 was -$27.00K.
- Aura Biosciences, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2025-03-31 was -$21.00K.
- Aura Biosciences, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for the quarter ending 2024-03-31 was $0.00.
- Aura Biosciences, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2025 was -$186.00K.
- Aura Biosciences, Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents, including disposal group and discontinued operations for fiscal 2024 was $0.00.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$200.00K 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | -$27.00K 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | -$186.00K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$26.00K 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$12.00K 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | -$21.00K 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |